Effect of TRK-100, a Stable Orally Active Prostacyclin Analogue, on Platelet Function and Plaque Size in Atherothrombotic Strokes
| Autor: | Yoshinari Isaka, Takenobu Kamada, Kazufumi Kimura, Masatoshi Imaizumi, Nobuo Handa |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Blood Platelets
Carotid Artery Diseases Male medicine.medical_specialty Arteriosclerosis Urology Administration Oral Prostacyclin Internal medicine Antithrombotic Humans Medicine Platelet Aged business.industry Ultrasound Thrombosis Hematology Middle Aged medicine.disease Epoprostenol Endocrinology Atheroma Platelet aggregation inhibitor Female business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Thrombosis and Haemostasis. 65:344-350 |
| ISSN: | 2567-689X 0340-6245 |
| Popis: | SummaryPatients with carotid atheromatous lesions were prospectively studied with indium-111 platelet imaging, platelet aggregability and B-mode real-time ultrasound tests to determine the shortterm effects of orally active prostacyclin analogue TRK-100 (40 μg, three times daily for 4 weeks). To establish baseline values, all patients underwent indium-111 platelet imaging, platelet aggregation study and B-mode ultrasound. The results were positive for carotid plaque and platelet accumulation. Visual analysis showed repeated platelet scintigrams to be unchanged in five patients without antithrombotic therapy; repeated ultrasound studies showed no change in eight of ten plaques, while one showed progression and one regression of the plaque. In five TRK-100 treated patients, five of seven lesions with platelet accumulation at the baseline became negative, and two remained unchanged during the treatment; repeated B-mode ultrasound tests indicated eight of nine plaques remained unchanged, while one showed plaque size reduction. Quantitative analysis demonstrated that, TRK-L00 significantly reduced the ADP aggregation (1 μM) from 55.2 ± 21.3"/" to 24.0 ± 14.7% (± Sp; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|